Immune depression or anergy in cancer patients has been well documented, and attempts to actively stimulate both nonspecific and specific antitumor immune reactions in cancer patients might well be thwarted by intrinsic defects in the ability of the host to respond. The passive administration of immune reagents such as serum, cells, or subcellular products that might be capable of reacting against the tumor independent of the host's immune competence has thus been an attractive area of investigation in tumor immunotherapy. Attempts to supply the tumor-bearing host, both animal and human, with normal serum or plasma (e.g., Moore et al., 1957; Albo et al., 1968) or normal allogeneic lymphocytes (e.g., Woodruff and Nolan, 1963; Symes et al., 1968; Moore and Gerner, 1970; Yonemoto and Terasaki, 1972) have been universally unsuccessful, and recent attempts have focused on the use of previously sensitized immune components.
ASJC Scopus subject areas
- Cancer Research